source
- Biogen's anti-tau Alzheimer drug BIIB080 fails primary endpoint in Phase 2, but shows slower declineBiogen reported results of its Phase 2 trial of BIIB080, a tau-targeting therapy for Alzheimer’s disease. The study’s primary endpoint was not met, meaning the drug did not achieve the pre-specifi…
- Regenxbio reports positive Duchenne gene therapy trial results, targets FDA approval by 2027Regenxbio announced that its gene therapy for Duchenne muscular dystrophy achieved the required endpoints in a pivotal clinical trial. The data met the study's predefined criteria, which the compa…